Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:98-107
Published online before print December 19, 2005, doi: 10.1161/CIRCULATIONAHA.105.561449
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
113/1/98    most recent
CIRCULATIONAHA.105.561449v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lutgens, E.
Right arrow Articles by Cleutjens, K.B.J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lutgens, E.
Right arrow Articles by Cleutjens, K.B.J.M.
Related Collections
Right arrow Pathophysiology
Right arrow Genetically altered mice
Right arrow Genomics
Right arrow Other Vascular biology

(Circulation. 2006;113:98-107.)
© 2006 American Heart Association, Inc.


Vascular Medicine

Disruption of the Cathepsin K Gene Reduces Atherosclerosis Progression and Induces Plaque Fibrosis but Accelerates Macrophage Foam Cell Formation

E. Lutgens, MD, PhD*; S.P.M. Lutgens, MSc*; B.C.G. Faber, PhD; S. Heeneman, PhD; M.M.J. Gijbels, PhD; M.P.J. de Winther, PhD; P. Frederik, PhD; I. van der Made, MSc; A. Daugherty, PhD; A.M. Sijbers, PhD; A. Fisher, PhD; C.J. Long, PhD; P. Saftig, PhD; D. Black, PhD; M.J.A.P. Daemen, MD, PhD; K.B.J.M. Cleutjens, PhD

From the Departments of Pathology (E.L., S.P.M.L., B.C.G.F., S.H., M.M.J.G., M.J.A.P.D., K.B.J.M.C.), Molecular Genetics (M.M.J.G., M.P.J.d.W., I.v.d.M.), and Electron Microscopy (P.F.), Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, the Netherlands; the University of Kentucky (A.D.), Lexington; Organon Scotland (A.M.S., A.F., C.J.L., D.B.), Newhouse, Scotland; and the Biochemical Institute (P.S.), University of Kiel, Kiel, Germany.

Correspondence to E. Lutgens, MD, PhD, Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, PO Box 616, 6200 MD Maastricht, The Netherlands. E-mail E.Lutgens{at}path.unimaas.nl

Received May 22, 2005; revision received September 25, 2005; accepted October 20, 2005.

Background— Cathepsin K (catK), a lysosomal cysteine protease, was identified in a gene-profiling experiment that compared human early plaques, advanced stable plaques, and advanced atherosclerotic plaques containing a thrombus, where it was highly upregulated in advanced stable plaques.

Methods and Results— To assess the function of catK in atherosclerosis, catK–/–/apolipoprotein (apo) E–/– mice were generated. At 26 weeks of age, plaque area in the catK–/–/apoE–/– mice was reduced (41.8%) owing to a decrease in the number of advanced lesions as well as a decrease in individual advanced plaque area. This suggests an important role for catK in atherosclerosis progression. Advanced plaques of catK–/–/apoE–/– mice showed an increase in collagen content. Medial elastin fibers were less prone to rupture than those of apoE–/– mice. Although the relative macrophage content did not differ, individual macrophage size increased. In vitro studies of bone marrow derived–macrophages confirmed this observation. Scavenger receptor–mediated uptake (particularly by CD36) of modified LDL increased in the absence of catK, resulting in an increased macrophage size because of increased cellular storage of cholesterol esters, thereby enlarging the lysosomes.

Conclusions— A deficiency of catK reduces plaque progression and induces plaque fibrosis but aggravates macrophage foam cell formation in atherosclerosis.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Clin. Chem.Home page
N. Taglieri, W. Koenig, and J. C. Kaski
Cystatin C and Cardiovascular Risk
Clin. Chem., November 1, 2009; 55(11): 1932 - 1943.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Sun, M. Ishibashi, T. Seimon, M. Lee, S. M. Sharma, K. A. Fitzgerald, A. O. Samokhin, Y. Wang, S. Sayers, M. Aikawa, et al.
Free Cholesterol Accumulation in Macrophage Membranes Activates Toll-Like Receptors and p38 Mitogen-Activated Protein Kinase and Induces Cathepsin K
Circ. Res., February 27, 2009; 104(4): 455 - 465.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Guo, I. Bot, R. de Nooijer, S. J. Hoffman, G. B. Stroup, E. A.L. Biessen, G. M. Benson, P. H.E. Groot, M. Van Eck, and T. J.C. Van Berkel
Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice
Cardiovasc Res, February 1, 2009; 81(2): 278 - 285.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. Hofnagel and H. Robenek
Cathepsin K: boon or bale for atherosclerotic plaque stability?
Cardiovasc Res, February 1, 2009; 81(2): 242 - 243.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-F. Cailhier, I. Sirois, P. Laplante, S. Lepage, M.-A. Raymond, N. Brassard, A. Prat, R. V. Iozzo, A. V. Pshezhetsky, and M.-J. Hebert
Caspase-3 Activation Triggers Extracellular Cathepsin L Release and Endorepellin Proteolysis
J. Biol. Chem., October 3, 2008; 283(40): 27220 - 27229.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. L. Welch, Y. Sun, B. J. Arey, V. Lemaitre, N. Sharma, M. Ishibashi, S. Sayers, R. Li, A. Gorelik, N. Pleskac, et al.
Spontaneous Atherothrombosis and Medial Degradation in Apoe-/-, Npc1-/- Mice
Circulation, November 20, 2007; 116(21): 2444 - 2452.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. P. M. Lutgens, K. B. J. M. Cleutjens, M. J. A. P. Daemen, and S. Heeneman
Cathepsin cysteine proteases in cardiovascular disease
FASEB J, October 1, 2007; 21(12): 3029 - 3041.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
E. Suganuma, V. R. Babaev, M. Motojima, Y. Zuo, N. Ayabe, A. B. Fogo, I. Ichikawa, M. F. Linton, S. Fazio, and V. Kon
Angiotensin Inhibition Decreases Progression of Advanced Atherosclerosis and Stabilizes Established Atherosclerotic Plaques
J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2311 - 2319.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y. S. Chatzizisis, A. U. Coskun, M. Jonas, E. R. Edelman, C. L. Feldman, and P. H. Stone
Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling: Molecular, Cellular, and Vascular Behavior
J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2379 - 2393.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. A. Jaffer, D.-E. Kim, L. Quinti, C.-H. Tung, E. Aikawa, A. N. Pande, R. H. Kohler, G.-P. Shi, P. Libby, and R. Weissleder
Optical Visualization of Cathepsin K Activity in Atherosclerosis With a Novel, Protease-Activatable Fluorescence Sensor
Circulation, May 1, 2007; 115(17): 2292 - 2298.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Kitamoto, G. K. Sukhova, J. Sun, M. Yang, P. Libby, V. Love, P. Duramad, C. Sun, Y. Zhang, X. Yang, et al.
Cathepsin L Deficiency Reduces Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Knockout Mice
Circulation, April 17, 2007; 115(15): 2065 - 2075.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
X. W. Cheng, K. Obata, M. Kuzuya, H. Izawa, K. Nakamura, E. Asai, T. Nagasaka, M. Saka, T. Kimata, A. Noda, et al.
Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure
Hypertension, November 1, 2006; 48(5): 979 - 987.
[Abstract] [Full Text] [PDF]